The purpose of this study is to infusion BCMA CAR-T cells to the patients with relapsed and
refractory multiple myeloma(MM), to assess the safety and feasibility of this strategy. The
CAR enables the T cell to recognize and kill the MM cells through the recognition of BCMA, a
protein expressed of the surface of the malignant plasma cells in MM patients.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Henan Cancer Hospital
Collaborator:
The Pregene (ShenZhen) Biotechnology Company, Ltd.